Previous 10 | Next 10 |
The electric vehicle sector is mostly higher after riding out some negative news yesterday with Lucid Group (LCID -3.3%) disclosing a SEC subpoena and Tesla (TSLA +3.0%) reportedly being probed over solar panel fire risk. Helping to boost sentiment, several Wall Street economists are mak...
Prothena has a drug candidate Birtamimab in phase three trials and is close to approval. The company has a promising pipeline in some high-revenue neurodegenerative disease fields. The company has very promising cash opportunities in the next five years as well as having over $600...
DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior manage...
Biogen's struggles with Aduhelm - its newly approved Azheimer's therapy - have been well documented - but the company is taking some small steps in the right direction. Meanwhile, Cassava Sciences recently took a significant step to restoring its own reputation - and share price - aft...
Investors are rushing back into electric vehicle stocks after the weekend signing of the bipartisan infrastructure bill. Proterra (PRTA +2.6%), Volta (VLTA +8.4%), GreenPower Motor GP, Electrameccanica Vehicles (SOLO +2.4%), Lordstown Motors (RIDE +5.4%), Electric Last Mile Solutions (MILE -0...
Prothena (NASDAQ:PRTA): Q3 GAAP EPS of $2.13 misses by $0.15. Revenue of $139.17M misses by $0.88M. Press Release For further details see: Prothena EPS misses by $0.15, misses on revenue
Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-end cash and restricted cash position was $601.5 million Received $140 million from partner payments in third quarter fro...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s likely going to take a few years to get beyond the stark difference between pre-pandemic and post-pandemic worlds. In the U.S., it’s very much like before and after 9/11. But there are some worthy healthc...
DUBLIN, Ireland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its third quarter and first nin...
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that Chief Financial Officer Tran B. Nguyen has bee...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...